Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Non-Randomized, Open-Label, Dose Escalation, Single-Center Study to Determine the Safety, Bio-distribution, and Preliminary Effectiveness and Efficacy of 177Lu-TATE-EB-01（LNC1010）in Adult Subjects With SSTR2-positive Tumors

NCT05410743 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xiamen University as lead sponsor.

NCT NCT05410743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05410743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Non-Randomized, Open-Label, Dose Escalation, Single-Center Study to Determine the Safety, Bio-distribution, and Preliminary Effectiveness and Efficacy of 177Lu-TATE-EB-01（LNC1010）in Adult Subjects With SSTR2-positive Tumors
Lead sponsor
The First Affiliated Hospital of Xiamen University
Phase
Phase 1/2
Overall status
Completed
Start date
June 1, 2022
Completion date
March 24, 2025
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sstr2-positive tumors